

Glen Reid

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/701141/publications.pdf>

Version: 2024-02-01

101
papers

7,392
citations

70961

41
h-index

54797

84
g-index

103
all docs

103
docs citations

103
times ranked

9959
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and activity of microRNA-loaded micelles in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. <i>Lancet Oncology</i> , The, 2017, 18, 1386-1396.	5.1	508
2	The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 9244-9249.	3.3	478
3	Haemolysis during Sample Preparation Alters microRNA Content of Plasma. <i>PLoS ONE</i> , 2011, 6, e24145.	1.1	442
4	Circulating microRNAs: Association with disease and potential use as biomarkers. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 193-208.	2.0	421
5	Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 417-25.	1.9	371
6	Characterization of the Transport of Nucleoside Analog Drugs by the Human Multidrug Resistance Proteins MRP4 and MRP5. <i>Molecular Pharmacology</i> , 2003, 63, 1094-1103.	1.0	346
7	Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). <i>Biochemical Journal</i> , 2003, 371, 361-367.	1.7	291
8	The Impact of Hemolysis on Cell-Free microRNA Biomarkers. <i>Frontiers in Genetics</i> , 2013, 4, 94.	1.1	266
9	Characterization of the MRP4- and MRP5-mediated Transport of Cyclic Nucleotides from Intact Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 17664-17671.	1.6	233
10	Characterization of Drug Transport by the Human Multidrug Resistance Protein 3 (ABCC3). <i>Journal of Biological Chemistry</i> , 2001, 276, 46400-46407.	1.6	227
11	Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. <i>Annals of Oncology</i> , 2013, 24, 3128-3135.	0.6	221
12	Interactions between Hepatic Mrp4 and Sult2a as Revealed by the Constitutive Androstane Receptor and Mrp4 Knockout Mice. <i>Journal of Biological Chemistry</i> , 2004, 279, 22250-22257.	1.6	211
13	Evidence for Two Interacting Ligand Binding Sites in Human Multidrug Resistance Protein 2 (ATP) Tj ETQq1 1 0.784314 rgBT /Overloc 177	1.6	177
14	Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. <i>Epigenomics</i> , 2016, 8, 1079-1085.	1.0	176
15	Thiopurine Metabolism and Identification of the Thiopurine Metabolites Transported by MRP4 and MRP5 Overexpressed in Human Embryonic Kidney Cells. <i>Molecular Pharmacology</i> , 2002, 62, 1321-1331.	1.0	174
16	Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer. <i>Biophysical Reviews</i> , 2018, 10, 69-86.	1.5	146
17	Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1421-1433.	0.5	121
18	Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1184-1191.	0.5	115

#	ARTICLE	IF	CITATIONS
19	The Human Multidrug Resistance Protein MRP5 Transports Folates and Can Mediate Cellular Resistance against Antifolates. <i>Cancer Research</i> , 2005, 65, 4425-4430.	0.4	114
20	Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. <i>Journal of Clinical Pathology</i> , 2013, 66, 847-853.	1.0	104
21	YB-1, the E2F Pathway, and Regulation of Tumor Cell Growth. <i>Journal of the National Cancer Institute</i> , 2012, 104, 133-146.	3.0	102
22	The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction. <i>FASEB Journal</i> , 2007, 21, 3592-3605.	0.2	95
23	Cloning of a Human Renal "Aminohippurate Transporter, hROAT1. <i>Kidney and Blood Pressure Research</i> , 1998, 21, 233-237.	0.9	86
24	Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1923-1929.	0.5	82
25	Protein Kinase C Activation Downregulates Human Organic Anion Transporter 1-Mediated Transport through Carrier Internalization. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1959-1968.	3.0	79
26	microRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. <i>Oncotarget</i> , 2015, 6, 36675-36688.	0.8	79
27	miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. <i>Oncotarget</i> , 2015, 6, 23480-23495.	0.8	76
28	Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. <i>British Journal of Cancer</i> , 2015, 113, 963-969.	2.9	68
29	MiRScore: A novel "microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. <i>Molecular Oncology</i> , 2015, 9, 715-726.	2.1	67
30	A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 1467-1469.	2.5	66
31	Cell-free microRNAs: potential biomarkers in need of standardized reporting. <i>Frontiers in Genetics</i> , 2013, 4, 56.	1.1	60
32	Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 1333-1342.	6.6	54
33	Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. <i>Journal of Clinical Pathology</i> , 2013, 66, 854-861.	1.0	54
34	Genomic Structure and in Vivo Expression of the Human Organic Anion Transporter 1 (hOAT1) Gene. <i>Biochemical and Biophysical Research Communications</i> , 2000, 275, 623-630.	1.0	51
35	The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. <i>Antiviral Research</i> , 2004, 62, 1-7.	1.9	51
36	Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 603-610.	1.1	48

#	ARTICLE	IF	CITATIONS
37	An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2018, 7, 153.	1.0	47
38	A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis. <i>Npj Systems Biology and Applications</i> , 2018, 4, 20.	1.4	47
39	KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma. <i>Molecular Cancer</i> , 2016, 15, 44.	7.9	46
40	An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2014, 110, 510-519.	2.9	45
41	Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma. <i>Molecular Cancer Research</i> , 2015, 13, 1106-1118.	1.5	44
42	Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer. <i>Drug Metabolism Reviews</i> , 2010, 42, 590-611.	1.5	43
43	Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 258-272.	0.5	40
44	MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets. <i>Journal of Thoracic Disease</i> , 2015, 7, 1031-40.	0.6	39
45	The β 133p53 β isoform promotes an immunosuppressive environment leading to aggressive prostate cancer. <i>Cell Death and Disease</i> , 2019, 10, 631.	2.7	36
46	Exploring Mechanisms of MicroRNA Downregulation in Cancer. <i>MicroRNA (Sharjah, United Arab Emirates)</i> 10(1):36-40, 2019.	0.6	36
47	Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM). <i>PLoS ONE</i> , 2013, 8, e70940.	1.1	33
48	FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. <i>Carcinogenesis</i> , 2018, 39, 534-545.	1.3	32
49	Malignant mesothelioma. <i>Internal Medicine Journal</i> , 2010, 40, 742-750.	0.5	31
50	ZIC1 Is Silenced and Has Tumor Suppressor Function in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1317-1328.	0.5	30
51	Mutational Analysis of Hedgehog Signaling Pathway Genes in Human Malignant Mesothelioma. <i>PLoS ONE</i> , 2013, 8, e66685.	1.1	29
52	A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma. <i>Molecular Oncology</i> , 2018, 12, 58-73.	2.1	27
53	Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future. <i>Frontiers in Oncology</i> , 2020, 10, 105.	1.3	27
54	Validation of tissue microarray technology in malignant pleural mesothelioma. <i>Pathology</i> , 2011, 43, 128-132.	0.3	26

#	ARTICLE	IF	CITATIONS
55	Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 221.	1.8	26
56	Cilengitide Inhibits Attachment and Invasion of Malignant Pleural Mesothelioma Cells through Antagonism of Integrins $\alpha 5 \beta 1$ and $\alpha 5 \beta 2$. <i>PLoS ONE</i> , 2014, 9, e90374.	1.1	26
57	Asbestos-related cancers: the "Hidden Killer"™ remains a global threat. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 271-278.	1.1	25
58	Inflammation in malignant mesothelioma - friend or foe?. <i>Annals of Cardiothoracic Surgery</i> , 2012, 1, 516-22.	0.6	24
59	Blockade of Aquaporin 1 Inhibits Proliferation, Motility, and Metastatic Potential of Mesothelioma <i>In Vitro</i> but not in an <i>In Vivo</i> Model. <i>Disease Markers</i> , 2015, 2015, 1-9.	0.6	23
60	Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase. <i>Journal of Rnai and Gene Silencing</i> , 2009, 5, 321-30.	1.2	22
61	Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma – A multi-institutional study. <i>European Journal of Cancer</i> , 2016, 63, 64-73.	1.3	21
62	A rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5' RACE and a molecular beacon probe. <i>Nucleic Acids Research</i> , 2010, 38, e19-e19.	6.5	20
63	A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2016, 114, 524-531.	2.9	20
64	Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 150, 102949.	2.0	20
65	Exploiting microRNAs As Cancer Therapeutics. <i>Targeted Oncology</i> , 2017, 12, 163-178.	1.7	18
66	Biomarkers in malignant pleural mesothelioma: current status and future directions. <i>Journal of Thoracic Disease</i> , 2018, 10, S1003-S1007.	0.6	17
67	High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. <i>Lung Cancer</i> , 2019, 130, 35-41.	0.9	17
68	Molecular biomarkers in malignant mesothelioma: state of the art. <i>Pathology</i> , 2011, 43, 201-212.	0.3	16
69	<i>SFRP</i> Tumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma. <i>Disease Markers</i> , 2017, 2017, 1-10.	0.6	16
70	Abstract 3976: Targeted delivery of a synthetic microRNA-based mimic as an approach to cancer therapy. <i>Cancer Research</i> , 2015, 75, 3976-3976.	0.4	15
71	Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma. <i>Oncotarget</i> , 2019, 10, 4125-4138.	0.8	13
72	Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma. <i>Frontiers in Genetics</i> , 2017, 8, 70.	1.1	12

#	ARTICLE	IF	CITATIONS
73	The importance of RT-qPCR primer design for the detection of siRNA-mediated mRNA silencing. BMC Research Notes, 2011, 4, 148.	0.6	11
74	BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state. PLoS ONE, 2018, 13, e0203003.	1.1	10
75	When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. Frontiers in Endocrinology, 2019, 10, 89.	1.5	10
76	The Potency of siRNA-Mediated Growth Inhibition Following Silencing of Essential Genes Is Dependent on siRNA Design and Varies With Target Sequence. Oligonucleotides, 2009, 19, 317-328.	2.7	9
77	The analysis of novel microRNA mimic sequences in cancer cells reveals lack of specificity in stem-loop RT-qPCR-based microRNA detection. BMC Research Notes, 2017, 10, 600.	0.6	9
78	Phenotypic screen for oxygen consumption rate identifies an anti-cancer naphthoquinone that induces mitochondrial oxidative stress. Redox Biology, 2020, 28, 101374.	3.9	9
79	YB-1 Knockdown Inhibits the Proliferation of Mesothelioma Cells through Multiple Mechanisms. Cancers, 2020, 12, 2285.	1.7	8
80	Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population. JTO Clinical and Research Reports, 2020, 1, 100075.	0.6	8
81	Response to "An innovative mesothelioma treatment based on mir-16 mimic loaded EGFR targeted minicells (TargomiRs)". Translational Lung Cancer Research, 2018, 7, S60-S61.	1.3	7
82	THE MULTIDRUG RESISTANCE PROTEINS 3"7. , 2003, , 445-458.		6
83	MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients. Genomics Data, 2016, 9, 44-49.	1.3	5
84	Asbestos and Zeolites: from A to Z via a Common Ion. Chemical Research in Toxicology, 2021, 34, 936-951.	1.7	5
85	Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways. , 2019, 2, 1193-1206.		5
86	Zeolites ameliorate asbestos toxicity in a transgenic model of malignant mesothelioma. FASEB BioAdvances, 2019, 1, 550-560.	1.3	4
87	P1.05-021 circRNAs: Potential Novel Biomarkers for the Early Detection of Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S626-S627.	0.5	3
88	Editorial: Emerging Therapies for Malignant Mesothelioma. Frontiers in Oncology, 2020, 10, 939.	1.3	3
89	Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?. Annals of Cardiothoracic Surgery, 2012, 1, 481-6.	0.6	3
90	Differential Expression of BARD1 Isoforms in Melanoma. Genes, 2021, 12, 320.	1.0	2

#	ARTICLE	IF	CITATIONS
91	MTE29.02 Advances in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S182-S184.	0.5	1
92	OA02.05 Expression of miR-223 in Mesothelioma Xenografts Originates from Stromal Cells in the Tumor Microenvironment. Journal of Thoracic Oncology, 2017, 12, S248.	0.5	1
93	Asbestos and the Pathophysiology of Mesothelioma. , 2019, , 19-33.		1
94	Covalent binding of molecules to plasma immersion ion implantation-activated microparticles for delivery into cells. Engineering Reports, 2020, 2, e12087.	0.9	1
95	Does miR-1 Play a Role in Malignant Pleural Mesothelioma Development and Progression?. Chest, 2013, 144, 1971.	0.4	0
96	Welcome Message from Conference Co-Convenors. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 1-1.	0.7	0
97	MicroRNAs and Cancer. , 2015, , 67-90.		0
98	Using a multidisciplinary approach to combat the burden of asbestos-related disease. Medical Journal of Australia, 2016, 204, 52-52.	0.8	0
99	P3.03-007 miR-137 Acts as a Tumor Suppressor via the Down-Regulation of YB-1 in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S1347-S1348.	0.5	0
100	ED13.02 Tissue-Based Biomarkers. Journal of Thoracic Oncology, 2017, 12, S57-S58.	0.5	0
101	OA02.03 Circulating Fibroblast Growth Factor 18 is Elevated in Malignant Pleural Mesothelioma Patients - A Multi-Institutional Study. Journal of Thoracic Oncology, 2017, 12, S247-S248.	0.5	0